Synthesis and cytotoxic evaluation of some novel sulfonamide derivatives against a few human cancer cells

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 4, 2011, Pages 741-748

  Mirian, Mina ^a   Zarghi, Afshin ^b   Sadeghi, Sedighe ^a   Tabaraki, Parisa ^c   Tavallaee, Mojdeh ^c   Dadrass, Orkideh ^c   Sadeghi Aliabadi, Hojjat ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

HeLa; MCF 7; MDA MB 468; MTT assay; Sulfonamides

Indexed keywords

4 ACETAMIDO 4 FLUOROPHENYL BENZENESULFONAMIDE; 4 ACETAMIDO 4 METHOXYPHENYL BENZENESULFONAMIDE; 4 ACETAMIDO 4 METHYLPHENYL BENZENESULFONAMIDE; 4 ACETAMIDO 4 PHENYL ENZENESULFONAMIDE; 4 AMINO 4 FLUOROPHENYL BENZENESULFONAMIDE; 4 AMINO 4 METHOXYPHENYL BENZENESULFONAMIDE; 4 AMINO 4 METHYLPHENYL BENZENESULFONAMIDE; 4 AMINO 4 PHENYL BENZENESULFONAMIDE; 4 AZIDO 4 FLUOROPHENYL BENZENESULFONAMIDE; 4 AZIDO 4 METHOXYPHENYL BENZENESULFONAMIDE; 4 AZIDO 4 METHYLPHENYL BENZENESULFONAMIDE; 4 AZIDO 4 PHENYL BENZENESULFONAMIDE; 4 METHYL SULFAMIDO 4 FLUOROPHENYL BENZENESULFONAMIDE; 4 METHYL SULFAMIDO 4 METHOXYPHENYL BENZENESULFONAMIDE; 4 METHYL SULFAMIDO 4 METHYLPHENYL BENZENESULFONAMIDE; 4 METHYL SULFAMIDO 4 PHENYL BENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; IC 50;

EID: 84859549325     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Supuran CT, Casini A and Scozzafava A. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev. (2003) 23: 535-558.
2. Mak NK, Kok TW, Wong RN, Lam SW, Lau YK, Leung WN, Cheung NH, Huang DP, Yeung LL and Chang CK. Photodynamic activities of sulfonamide derivatives of porphycene on nasopharyngeal carcinoma cells. J. Biomed. Sci. (2003) 10: 418-429.
3. Khodarahmi GA, Chen PY, Hakimelahi GH and Chern JW. Synthesis and primary cytotoxic screening of some 3-sulfonamide substituted benzamido-benzimidazolones. Iranian J. Pharm. Res. (2005) 4: 43-56.
4. Bouchain G, Leit S, Frechette S, Khalil EA, Lavoie R, Moradei O, Woo SH, Fournel M, Yan PT, Kalita A, Trachy-Bourget MC, Beaulieu C, Li Z, Robert MF, MacLeod AR, Besterman JM and Delorme D. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J. Med. Chem. (2003) 46: 820-830.
5. Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P and Schellens JH. Early clinical studies group of the European organization for research and treatment of cancer. Population pharmacokinetics of the novel anticancer agent E7070 during four phases I studies: model building and validation. J. Clin. Oncol. (2002) 20: 4065-4073.
6. Baur M, Gneist M, Owa T and Dittrich C. Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070). Melanoma Res. (2007) 17: 329-331.
7. Beumer JH, Hillebrand MJ, Pluim D, Rosing H, Foley K, Yule SM, Schellens JH and Beijnen JH. Human metabolism of [(14) C] indisulam following i.v. infusion in cancer patients. Invest. New Drugs (2005) 23: 317-330.
8. Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12: 283-287.
9. Shamsa F and Amani L. Determination of sulfamethoxazole and trimethoprim in pharmaceuticals by Visible and UV spectrophotometry. Iranian J. Pharm. Res. (2006) 5: 31-36.
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods (1983) 65: 55-63.
11. Sadeghi-aliabadi H, Tabarzadi M and Zarghi A. Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives. IL Farmaco (2004) 59: 645-649.
12. Scozzafava A, Owa T, Mastrolorenzo A and Supuran CT. Anticancer and antiviral sulfonamides. Curr. Med. Chem. (2003) 10: 925-953.
13. Casini A, Scozzafava A and Supuran CT. Sulfonamide derivatives with protease inhibitory action as anticancer, anti-inflammatory and antiviral agents. Expert Opin. Ther. Pat. (2002) 12: 1307-1327.
14. Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH and Beijnen JH. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs (2002) 13: 807-814.
15. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, Narita N, Saijo N and Nishio K. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs (2001) 19: 219-227.
16. Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L and Reck M. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. (2007) 13: 1816-1822.
17. Abbate F, Casini A, Owa T, Scozzafava A and Supuran CT. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14: 217-223.
18. Subbaramaiah K and Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. (2003) 24: 96-102.